LIVE MARKET TRACKER :   BSE SENSEX   31626.63      |    NSE NIFTY 9872.60    
GLOBAL MARKETS :  NASDAQ 6370.5898   -0.8765%    |    FSI London 7301.29   -0.13%    |    NIKKEI Japan 20397.58   +0.00%
  USD GBP EUR CAD AUD INR
USD - 0.7419 0.8438 1.2373 1.2600 65.1720
GBP 1.3481 - 1.1373 1.6681 1.6984 87.8493
EUR 1.1855 0.8800 - 1.4667 1.4935 77.2259
CAD 0.8084 0.6001 0.6821 - 1.0187 52.6870
AUD 0.7942 0.5890 0.6698 0.9821 - 51.7090
INR 0.0154 0.0114 0.0130 0.0190 0.0194 -
Indian-Commodity  :  Top News  :  AstraZeneca Pharma to launch Osimertinib tablets in India

AstraZeneca Pharma to launch Osimertinib tablets in India (24-Jul-2017)

AstraZeneca Pharma India will be launching Osimertinib 40 mg and 80 mg (Tagrisso) in India on July 27, 2017. Osimertinib 40 mg and 80 mg (Tagrisso) is an oral anti-cancer drug for management of lung cancer.

It is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an appropriate test, whose disease has progressed on or after EGFR TKI therapy. Osimertinib (Tagrisso) is the product of AstraZeneca group and has been approved in over 45 countries, including US, EU, Japan, China and other Asian countries.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.



Top News Today
Nucleus Software launches semi-closed PPI wallet
(25-Sep-2017)

Nucleus Software launches semi-closed PPI walletNucleus Software Exports has launched semi-closed PPI wallet product under the brand name 'PaySe', which will be operated in a controlled environment, on September 22, 2017. The company shall be initiating......click on news to read complete article.

Havells renews Commercial Paper issued to UTI Mutual Fund for Rs 150 crore
(25-Sep-2017)

Havells renews Commercial Paper issued to UTI Mutual Fund for Rs 150 croreHavells India has renewed the Commercial Paper issued to UTI Mutual Fund for an amount of Rs 150 crore for a period of 91 days at 6.23%. All other terms and conditions remain the same as intimated earlier......click on news to read complete article.

Ashapura Intimates opens EBO store at Ranchi
(25-Sep-2017)

Ashapura Intimates opens EBO store at RanchiAshapura Intimates Fashion has opened an Exclusive Brand Outlet (EBO) on September 25, 2017 at Mangal Kunj Apartment, Kanke Road, Ranchi, Jharkhand.Ashapura Intimates Fashion is engaged in the business......click on news to read complete article.

International Stock News
Asian markets trade mostly lower in early deals on Monday
(25-Sep-2017)

Asian markets trade mostly lower in early deals on MondayMost of the Asian equity benchmarks are trading down in the early deals on Monday, following the lackluster cues from Wall Street and concerns about China's economy. Investors digested election results......click on news to read complete article.

US markets end flat on geopolitical concerns
(23-Sep-2017)

US markets end flat on geopolitical concernsThe US markets ended the lackluster session near their neutral lines on Friday on geopolitical concerns amid an escalating war of words between North Korean leader Kim Jong Un and President Donald Trump.......click on news to read complete article.

Asian markets trade lower on heightened geopolitical tensions
(22-Sep-2017)

Asian markets trade lower on heightened geopolitical tensionsThe Asian markets are showing a weak trend on Friday, on renewed geopolitical worries after a report that North Korea could respond to fresh sanctions with a hydrogen bomb in the Pacific. A news report......click on news to read complete article.

 

     
  
Recent Top News News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.